ABT-101

ABT-101 is a potent, orally administered, irreversible, mutant-selective small molecule tyrosine kinase inhibitor (TKI) developed by Anbogen Therapeutics. It targets several oncogenic kinases, most notably the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ERBB2). ABT-101 demonstrates superior selectivity against HER2 exon 20 insertion mutations and has shown significant inhibition of tumor growth in preclinical models harboring these mutations. The drug is being investigated primarily for non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertions but may also have potential in other solid tumors with similar kinase domain mutations. Clinical trials are ongoing to determine its safety, recommended phase 2 dose, and preliminary antitumor activity[1][5][7].

Other names

ABT 101ABT101ABT-101